RecruitingPhase 2NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Studying Plasma cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Nemtabrutinib(drug)
- Enrollment
- 490 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2029
Study locations (30)
- Highlands Oncology Group ( Site 2728), Springdale, Arkansas, United States
- University of California San Diego Moores Cancer Center ( Site 2717), La Jolla, California, United States
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724), Torrance, California, United States
- Colorado Blood Cancer Institute ( Site 2726), Denver, Colorado, United States
- The University of Louisville, James Graham Brown Cancer Center ( Site 2729), Louisville, Kentucky, United States
- Mayo Clinic - Rochester ( Site 2706), Rochester, Minnesota, United States
- Astera Cancer Care ( Site 2732), East Brunswick, New Jersey, United States
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704), Hackensack, New Jersey, United States
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708), Fargo, North Dakota, United States
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas, Texas, United States
- Medical Oncology Associates (Summit Cancer Centers) ( Site 2710), Spokane, Washington, United States
- Hospital Aleman ( Site 0102), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103), Buenos Aires, Buenos Aires F.D., Argentina
- Fundacion Estudios Clinicos ( Site 0112), Rosario, Santa Fe Province, Argentina
- FUNDALEU ( Site 0104), Caba, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04728893 on ClinicalTrials.govOther trials for Plasma cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07509086IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell LeukemiaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06517017Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaUniversity of Utah
- RECRUITINGPHASE2NCT07106684ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell LeukemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT06730256A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07052916A Music Therapy Study for Blood Cancer Survivors With Cognitive DifficultiesMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2, PHASE3NCT07202091Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)Monash University
- RECRUITINGEARLY PHASE1NCT06718270a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaShanghai Changzheng Hospital
- RECRUITINGPHASE2NCT06140966Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology